Matthew Wanat to Rivaroxaban
This is a "connection" page, showing publications Matthew Wanat has written about Rivaroxaban.
Connection Strength
0.347
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.238
-
Novel oral anticoagulants: a review of new agents. Postgrad Med. 2013 Jul; 125(4):103-14.
Score: 0.110